Literature DB >> 26390968

Kidney cancer: Sunitinib: 2/1 is superior to 4/2.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26390968     DOI： 10.1038/nrurol.2015.239

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.

Authors:  J L Lee; M K Kim; I Park; J-H Ahn; D H Lee; H M Ryoo; C Song; B Hong; J H Hong; H Ahn
Journal:  Ann Oncol       Date:  2015-09-07       Impact factor: 32.976
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.